The DOI matches its Crossref record.
Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study
Open accessAbstract
BACKGROUND: Rotavirus is the main cause of severe acute gastroenteritis in children in Africa. Monovalent human rotavirus vaccine (RV1) was added into Malawi's infant immunisation schedule on Oct 29, 2012. We aimed to assess the impact and effectiveness of RV1 on rotavirus gastroenteritis in the 2 years after introduction. METHODS: From Jan 1, 2012, to June 30, 2014, we recruited children younger than 5 years who were admitted into Queen Elizabeth Central Hospital, Blantyre, Malawi, with acute gastroenteritis. We assessed stool samples from these children for presence of rotavirus with use of ELISA and we genotyped rotaviruses with use of RT-PCR. We compared rotavirus detection rates in stool samples and incidence of hospital admittance for rotavirus in children from Jan 1 to June 30, in the year before vaccination (2012) with the same months in the 2 years after vaccination was introduced (2013 and 2014). In the case-control portion of our study, we recruited eligible rotavirus-positive children from the surveillance platform and calculated vaccine effectiveness (one minus the odds ratio of vaccination) by comparing infants with rotavirus gastroenteritis with infants who tested negative for rotavirus, and with community age-matched and neighbourhood-matched controls. FINDINGS: We enrolled 1431 children, from whom we obtained 1417 stool samples (99%). We detected rotavirus in 79 of 157 infants (50%) before the vaccine, compared with 57 of 219 (40%) and 52 of 170 (31%) in successive calendar years after vaccine introduction (p=0·0002). In the first half of 2012, incidence of rotavirus hospital admission was 269 per 100,000 infants compared with 284 in the same months of 2013 (rise of 5·8%, 95% CI -23·1 to 45·4; p=0·73) and 153 in these months in 2014 (a reduction from the prevaccine period of 43·2%, 18·0-60·7; p=0·003). We recruited 118 vaccine-eligible rotavirus cases (median age 8·9 months; IQR 6·6-11·1), 317 rotavirus-test-negative controls (9·4 months; 6·9-11·9), and 380 community controls (8·8 months; 6·5-11·1). Vaccine effectiveness for two doses of RV1 in rotavirus-negative individuals was 64% (95% CI 24-83) and community controls was 63% (23-83). The point estimate of effectiveness was higher against genotype G1 than against G2 and G12. INTERPRETATION: Routine use of RV1 reduced hospital admissions for several genotypes of rotavirus in children younger than 5 years, especially in infants younger than 1 year. Our data support introduction of rotavirus vaccination at the WHO recommended schedule, with continuing surveillance in high-mortality countries. FUNDING: Wellcome Trust, GlaxoSmithKline Biologicals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bányai, K., Estes, M. K., Martella, V., & Parashar, U. D. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31128-0 · Cited by 445
Self-citationVaccines for preventing rotavirus diarrhoea: vaccines in use
Soares‐Weiser, K., MacLehose, H. G., Bergman, H., Ben‐Aharon, I., Nagpal, S., Goldberg, E., Pitan, F., & Cunliffe, N. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008521.pub3 · Cited by 381
Self-citationHarris, V. C., Armah, G., Fuentes, S., Korpela, K. E., Parashar, U., Victor, J. C., Tate, J., de Weerth, C., Giaquinto, C., Wiersinga, W. J., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw518 · Cited by 299
Self-citation
Metadata
- Authors
- Bar-Zeev, N., Kapanda, L., Tate, J. E., Jere, K. C., Iturriza-Gomara, M., Nakagomi, O., Mwansambo, C., Costello, A., Parashar, U. D., Heyderman, R. S., French, N., & Cunliffe, N. A.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 15
- Issue
- 4
- Pages
- 422-428
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2022086407
- Cited by
- 174
- References
- 0
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. https://app.cochat.ai/papers/10.1016/s1473-3099(14)71060-6
- The paper
- Bar-Zeev, N., Kapanda, L., Tate, J. E., Jere, K. C., Iturriza-Gomara, M., Nakagomi, O., Mwansambo, C., Costello, A., Parashar, U. D., Heyderman, R. S., French, N., & Cunliffe, N. A. (2015). Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(14)71060-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.